+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cough Suppressant Drugs Market - Global Forecast 2026-2032- Product Image
Cough Suppressant Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Cough Suppressant Drugs Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989771
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cough Suppressant Drugs Market is projected to reach USD 2.24 Billion in 2026. It is expected to continue growing at a CAGR of 4.90%, reaching USD 3.01 Billion by 2032.

The cough suppressant drugs market covers over-the-counter and prescription antitussive medicines used to reduce nonproductive cough and improve patient comfort during respiratory infections, allergic irritation, post-viral cough, and selected chronic respiratory conditions. Core product categories include dextromethorphan-based OTC cough medicines, prescription benzonatate, antihistamine-containing formulations, and tightly controlled opioid antitussives such as codeine or hydrocodone combinations where legally permitted.

Demand is supported by the recurring global burden of acute respiratory infections, seasonal influenza and respiratory syncytial virus activity, air pollution exposure, tobacco-related airway irritation, and a large consumer base seeking convenient symptom relief. At the same time, the cough suppressant drugs industry is shaped by evidence-based prescribing, pediatric safety restrictions, opioid risk mitigation, pharmacovigilance, and the need for formulations that align with modern consumer preferences, including alcohol-free, sugar-free, dye-free, and age-appropriate products.

Transformative Shifts in the Cough Suppressant Landscape

The market is moving away from broad, symptom-masking products toward safer, better-labeled, and more targeted antitussive therapies. Regulatory agencies and pediatric societies have reinforced caution around cough and cold medicines in young children, while opioid stewardship has reduced reliance on codeine- and hydrocodone-based cough suppressants. These shifts are increasing demand for non-opioid options, clearer dosing systems, child-resistant packaging, and pharmacist-guided product selection.

Retail pharmacy, e-commerce, and telehealth are also changing how consumers access cough medicines. Brands are competing on trust, label transparency, flavor, convenience, and compatibility with common comorbidities such as diabetes and hypertension. Manufacturers are strengthening supply resilience for active pharmaceutical ingredients, excipients, packaging components, and cold-season inventory planning as influenza, respiratory syncytial virus, COVID-19, and other respiratory virus surges continue to affect demand patterns.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across the cough suppressant drugs value chain. In research and development, AI-supported molecular modeling, literature mining, and safety signal analysis can help identify non-opioid antitussive candidates, optimize formulations, and evaluate drug-drug interaction risks earlier in development. Natural language processing can also support the review of clinical notes, adverse event reports, published evidence, and real-world evidence related to cough treatment outcomes.

Commercially, AI improves demand forecasting for seasonal respiratory products, helps retailers and distributors reduce stockouts, and supports compliant patient education through digital tools. However, AI adoption must be governed by validated datasets, privacy safeguards, human clinical oversight, and transparent model performance. The strongest use cases will be those that improve safety, access, pharmacovigilance, and evidence generation rather than replacing professional judgment.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific represents a high-volume opportunity due to large populations, expanding pharmacy access, urban air pollution exposure, and strong domestic pharmaceutical manufacturing in markets such as China, India, Japan, and South Korea. The region’s cough suppressant demand is influenced by seasonal respiratory infections, self-medication practices, rising consumer health awareness, and evolving national drug regulations that increasingly emphasize quality standards, labeling discipline, and pharmacovigilance.

North America remains a mature and highly regulated market, with the United States and Canada emphasizing OTC labeling, controlled-substance oversight, poison prevention, and evidence-based pediatric use. Latin America is driven by urbanization, air-quality concerns, branded generics, and improving retail pharmacy networks, while Europe is shaped by strict pharmacovigilance, national medicine controls, sustainability expectations, and strong consumer demand for safe self-care products. The Middle East is supported by private healthcare investment, retail pharmacy expansion, and GCC regulatory alignment, whereas Africa’s development is tied to affordability, access, respiratory infection burden, public health infrastructure, and the need to combat substandard or falsified medicines.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are benefiting from expanding community pharmacy access, growing OTC adoption, and gradual regulatory cooperation, although country-level rules, language requirements, and distribution structures remain important for market entry. GCC countries show demand for premium, imported, and locally registered cough suppressant products, supported by healthcare modernization, centralized procurement practices, private care expansion, and efforts to streamline medicine registration across member states.

The European Union offers a sophisticated but compliance-intensive environment defined by pharmacovigilance, multilingual labeling, medical device and medicine interface scrutiny where relevant, and national-level medicine controls. BRICS countries are central to both demand and supply because they combine large patient populations with major pharmaceutical manufacturing capacity, particularly in China, India, and Brazil, while also emphasizing domestic production and medicine access. G7 markets set many global expectations for safety, evidence, quality, pediatric caution, and post-market surveillance, while NATO countries increasingly view pharmaceutical supply resilience, essential medicine continuity, and emergency preparedness as part of broader health security.

Key Country Insights Across Major Cough Suppressant Markets

The United States is defined by FDA-regulated OTC drug requirements, controlled-substance scrutiny, poison center awareness, and strong retail pharmacy influence, while Canada emphasizes Health Canada oversight, bilingual labeling, and safe-use communication. Mexico and Brazil are important Latin American markets, with COFEPRIS and ANVISA shaping quality expectations, registration pathways, pharmacovigilance practices, and generic competition. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature pharmacy channels with national regulators such as the MHRA, BfArM, ANSM, AIFA, and AEMPS, making compliance, post-market monitoring, responsible advertising, and consumer trust central to market participation.

Russia remains a large respiratory care market with domestic supply considerations and evolving localization priorities, while China and India are pivotal due to population scale, manufacturing capacity, and expanding regulatory modernization through the NMPA and CDSCO. Japan’s market is influenced by PMDA oversight, aging demographics, high quality expectations, and preference for well-documented formulations. Australia is governed by the TGA and has a strong self-care culture supported by pharmacy advice, while South Korea combines MFDS oversight, advanced retail channels, digital health adoption, and innovation-oriented pharmaceutical capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize non-opioid antitussive innovation, pediatric-safe product strategies, and evidence-based claims supported by clinical data, pharmacovigilance, and real-world evidence. Portfolio planning should include alcohol-free, sugar-free, dye-free, and comorbidity-conscious formulations, along with packaging and dosing devices that reduce medication errors and support safe household storage.

Manufacturers and distributors should strengthen respiratory-season forecasting, diversify API and packaging sources, and build inventory playbooks for demand spikes linked to influenza, RSV, COVID-19, and regional pollution events. Commercial teams should invest in pharmacist education, compliant digital content, clear contraindication messaging, and region-specific labeling. Companies entering emerging markets should pair affordability with quality assurance, serialization, and anti-counterfeit controls to protect brand trust and patient safety.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with pharmaceutical market intelligence practices. The analysis synthesizes publicly available information from recognized regulatory bodies, public health agencies, peer-reviewed medical literature, pharmacovigilance guidance, medicine safety communications, pharmacopeial quality standards, and industry supply-chain observations related to antitussive drugs and respiratory care.

The methodology emphasizes triangulation across demand drivers, regulatory requirements, product categories, regional dynamics, access channels, and competitive behavior. Insights are validated against known safety frameworks for OTC cough medicines, prescription antitussives, pediatric use, opioid risk controls, drug quality standards, and post-market surveillance. No unsupported market sizing, market share, or speculative growth figures are included, ensuring the summary remains evidence-led and suitable for executive decision-making.

Conclusion

The cough suppressant drugs market is evolving from a traditional seasonal OTC category into a more regulated, safety-focused, and data-enabled segment of respiratory care. Opportunities remain strong where manufacturers can meet consumer demand for fast symptom relief while aligning with modern expectations for safe use, transparent labeling, responsible prescribing, and high-quality production.

Winning strategies will depend on non-opioid innovation, high-quality manufacturing, regional regulatory fluency, AI-enabled demand planning, and trusted engagement with pharmacists, clinicians, regulators, and consumers. Organizations that combine efficacy, safety, access, compliance, and supply resilience will be best positioned to compete in the global cough suppressant drugs market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cough Suppressant Drugs Market, by Product Form
7.1. Introduction
7.2. Capsule
7.2.1. Hard Capsule
7.2.2. Soft Gelatin Capsule
7.3. Drop
7.4. Lozenge
7.4.1. Flavored
7.4.2. Unflavored
7.5. Syrup
7.5.1. Sugar-Based
7.5.2. Sugar-Free
7.6. Tablet
7.6.1. Chewable Tablet
7.6.2. Conventional Tablet
7.6.3. Orally Disintegrating Tablet
8. Cough Suppressant Drugs Market, by Prescription Status
8.1. Introduction
8.2. Over The Counter
8.3. Prescription
9. Cough Suppressant Drugs Market, by Active Ingredient
9.1. Introduction
9.2. Benzonatate
9.3. Codeine
9.4. Dextromethorphan
9.5. Diphenhydramine
9.6. Guaifenesin
9.7. Herbal Extracts
9.7.1. Eucalyptus Oil
9.7.2. Honey
9.7.3. Thyme Extract
10. Cough Suppressant Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Cough Suppressant Drugs Market, by End User
11.1. Introduction
11.2. Ambulatory Center
11.3. Hospitals & Clinics
11.4. Homecare Setting
12. Cough Suppressant Drugs Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Cough Suppressant Drugs Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Cough Suppressant Drugs Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Alkem Laboratories Limited
16.2. Amneal Pharmaceuticals LLC
16.3. AstraZeneca plc
16.4. Aurobindo Pharma Limited
16.5. Aytu BioPharma, Inc.
16.6. Bayer Ag
16.7. Boehringer Ingelheim International GmbH
16.8. Cipla Limited
16.9. Dr. Reddy’s Laboratories Limited
16.10. GlaxoSmithKline plc
16.11. Glenmark Pharmaceuticals Limited
16.12. Haleon plc
16.13. Johnson & Johnson Service Inc.
16.14. Kenvue Inc.
16.15. Mayne Pharma Group Limited
16.16. Merck & Co., Inc.
16.17. Novartis AG
16.18. Perrigo Company plc
16.19. Pfizer Inc.
16.20. Prestige Consumer Healthcare Inc.
16.21. Reckitt Benckiser Group plc
16.22. Sanofi S.A.
16.23. Sun Pharmaceutical Industries Limited
16.24. Teva Pharmaceutical Industries Ltd.
16.25. The Procter & Gamble Company
16.26. Viatris Inc.
16.27. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2025 VS 2032 (%)
FIGURE 7. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2032 (%)
FIGURE 11. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HARD CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HARD CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HARD CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SOFT GELATIN CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SOFT GELATIN CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SOFT GELATIN CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DROP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DROP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DROP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL LOZENGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL LOZENGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL LOZENGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL FLAVORED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL FLAVORED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL FLAVORED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL UNFLAVORED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL UNFLAVORED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL UNFLAVORED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SYRUP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SYRUP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SYRUP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SUGAR-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SUGAR-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SUGAR-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SUGAR-FREE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SUGAR-FREE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SUGAR-FREE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CHEWABLE TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CHEWABLE TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CHEWABLE TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CONVENTIONAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CONVENTIONAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CONVENTIONAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ORALLY DISINTEGRATING TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ORALLY DISINTEGRATING TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ORALLY DISINTEGRATING TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL OVER THE COUNTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL OVER THE COUNTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL OVER THE COUNTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL BENZONATATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL BENZONATATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL BENZONATATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CODEINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL DEXTROMETHORPHAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL DEXTROMETHORPHAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL DEXTROMETHORPHAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL DIPHENHYDRAMINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL DIPHENHYDRAMINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL DIPHENHYDRAMINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GUAIFENESIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GUAIFENESIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GUAIFENESIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HERBAL EXTRACTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HERBAL EXTRACTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HERBAL EXTRACTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL EUCALYPTUS OIL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL EUCALYPTUS OIL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL EUCALYPTUS OIL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HONEY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HONEY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HONEY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL THYME EXTRACT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL THYME EXTRACT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL THYME EXTRACT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL AMBULATORY CENTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL AMBULATORY CENTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL AMBULATORY CENTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HOMECARE SETTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOMECARE SETTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HOMECARE SETTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 135. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 137. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 138. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 139. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 140. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 141. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 142. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 143. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 144. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. EUROPE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 159. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 160. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 161. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 162. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 163. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 164. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 165. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 166. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. AFRICA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 171. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 172. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 173. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 174. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 175. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 176. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 177. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 178. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. ASEAN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 182. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 183. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 184. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 185. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 186. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 187. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 188. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 189. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. GCC COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 204. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 205. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 206. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 207. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 208. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 209. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 210. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 211. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 212. BRICS COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 214. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 215. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 216. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 217. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 218. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 219. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 220. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 221. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 222. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. G7 COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 225. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 226. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 227. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 228. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 229. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 230. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 231. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 232. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 233. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 234. NATO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 249. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 250. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 251. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 252. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 253. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 254. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 255. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 256. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 257. CANADA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 258. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 259. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 260. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 261. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 262. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 263. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 264. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 265. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 266. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 267. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 268. MEXICO COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 291. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 293. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 294. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 295. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 296. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 297. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 298. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 299. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 300. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. GERMANY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 304. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 305. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 306. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 307. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 308. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 309. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 310. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 311. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. FRANCE COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 315. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 316. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 317. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 318. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 319. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 320. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 321. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 322. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 323. RUSSIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 324. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 326. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 327. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 328. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 329. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 330. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 331. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 332. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 333. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. ITALY COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 335. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 336. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 337. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 338. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 339. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 340. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 341. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 342. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 343. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 344. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 345. SPAIN COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 346. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 348. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 349. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY LOZENGE, 2017-2032 (USD MILLION)
TABLE 350. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY SYRUP, 2017-2032 (USD MILLION)
TABLE 351. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY TABLET, 2017-2032 (USD MILLION)
TABLE 352. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 353. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY ACTIVE INGREDIENT, 2017-2032 (USD MILLION)
TABLE 354. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY HERBAL EXTRACTS, 2017-2032 (USD MILLION)
TABLE 355. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 356. CHINA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 357. INDIA COUGH SUPPRESSANT DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 358. INDIA COUGH SUPPRESSANT DRUGS MARKET SIZE, BY PRODUCT FORM, 2017-2032 (USD MILLION)
TABLE 359. INDIA COUGH SUPPRE

Companies Mentioned

  • Alkem Laboratories Limited
  • Amneal Pharmaceuticals LLC
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Aytu BioPharma, Inc.
  • Bayer Ag
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Haleon plc
  • Johnson & Johnson Service Inc.
  • Kenvue Inc.
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Prestige Consumer Healthcare Inc.
  • Reckitt Benckiser Group plc
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.24 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.01 Billion
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Cough Syrup Market Report by Product Type, Age Group, Distribution Channel, and Region 2026-2034 - Product Image

Cough Syrup Market Report by Product Type, Age Group, Distribution Channel, and Region 2026-2034

  • Report
  • 141 Pages
  • Global
From
Antitussive Drugs - Global Strategic Business Report - Product Image

Antitussive Drugs - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Cough Syrups - Global Strategic Business Report - Product Image

Cough Syrups - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Cough Syrup - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Cough Syrup - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Chronic Cough Market Report 2026 - Product Image

Chronic Cough Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Market

The Antitussive market is a subset of the Cough and Cold Drugs market, which is composed of medications used to treat symptoms of the common cold, such as cough, sore throat, and congestion. Antitussives are a type of cough suppressant, which work by reducing the urge to cough and suppressing the reflex that causes coughing. Common ingredients in antitussives include dextromethorphan, codeine, and pholcodine. Antitussives are available in a variety of forms, including syrups, tablets, capsules, and lozenges. They are available both over-the-counter and by prescription, depending on the active ingredient. Some companies in the Antitussive market include GlaxoSmithKline, Pfizer, Novartis, Sanofi, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.